Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22442278 | 0.81 | MEN1 (0.35) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL23080052 | 0.80 | ALDH1A1 (0.34) | ALDH1A1DPP4LMNA | |
| SCHEMBL248983 | 0.79 | MEN1 (0.38) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL12057384 | 0.78 | ALDH1A1 (0.33) | ALDH1A1DPP4 | |
| SCHEMBL15373153 | 0.77 | ALDH1A1 (0.32) | ALDH1A1DPP4 | |
| SCHEMBL21235964 | 0.77 | ALDH1A1 (0.32) | ALDH1A1DPP4 | |
| SCHEMBL23005762 | 0.77 | ALDH1A1 (0.32) | ALDH1A1DPP4 | |
| SCHEMBL28756614 | 0.75 | ABCC4 (0.39) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL12057390 | 0.75 | ALDH1A1 (0.39) | ALDH1A1DPP4MEN1HTTKMT2A | |
| SCHEMBL17460039 | 0.74 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | claimed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | claimed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| CN-107698748-B | Dynamic polymer of hybrid cross-linked network and application thereof | 翁秋梅 | 2020-03-10 | — | — | CN | disclosed |
| EP-3197879-B1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-26 | — | — | EP | disclosed |
| EP-3087104-B1 | METHOD FOR CONTROLLED METATHESIS DEPOLYMERIZATION OF NATURAL RUBBER FROM NATURAL RUBBER LATEX | MICHELIN & CIE (FR) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018177989-A1 | NEW DITHIOSPIROKETAL COMPOUNDS AND USE THEREOF | ECOLE POLYTECHNIQUE (FR) | 2018-10-04 | — | — | WO | disclosed |
| EP-2310013-A1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | Merck Patent GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010017870-A1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
| US-6334890-B1 | COMPOSITION COMPRISED OF OXAZOLINE COMPOUND WITH SPECIFIED MELTING POINT AND ACOUSTIC LOSS VALUE, LONG CHAIN CARBAMATE, ALCOHOL COMPOUND, LIGHTFASTNESS COMPONENT, LIGHTFASTNESS ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | disclosed |
| US-6187082-B1 | COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | ALDH1A1 1200/4885DPP4 3606/4885MEN1 2871/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | ALDH1A1 2031/4885DPP4 1183/4885MEN1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.